Oncology spin-out Incanthera have completed a co-funding and co-development deal with US-based Technomark Life Sciences, advised by Epiphany Capital as part of the company’s Series A round.

The deal sees Technomark’s return to the UK market.

April 2012

Epiphany Capital recently organised and sponsored the UMI3 Lean Startup Day at the University of Manchester.
There were over 80 people in attendance and the event was a real success.

See a tweetdoc of the event feed here.


Event Programme:

Session 1:   The Lean Startup

Keynote: Joel Gascoigne (@joelgascgoine), Founder of Buffer & OnePage
“Introducing The Lean Startup: How Buffer went from idea to customer in 6 weeks”

Also featuring Martin Bryant (@martinsfp), Managing Editor at leading online tech blog The Next Web

Session 2:   Startup Stories

Demos, tips and lessons from 2 beta-stage startups:

TrueView will be launching its beta at the event with Founder, Andrew Ibbotson @AIbbotson

PostDesk (recently launched into beta) and its founder Sam England (@samengland)

 Session 3:   Panel Discussion

Panel features Martin, Andrew and Sam alongside:

Roy Shelton (@royshelton), entrepreneur, angel investor (DropJaw Ventures)
David Smith, Fund Manager at VC fund AXM Ventures

Presented by Dave Carter, CEO at Manchester Digital

Buffer is a tool for Twitter, LinkedIn and now Facebook, allowing users to schedule updates/tweets in advance of sending them. Using the lean framework, Joel founded the company in October 2010 and delivered the product to his first customer 6 weeks later. In January 2011 he hired his co-founder and closed their first funding round ($400k) from a number of Silicon Valley angels including Hiten Shah (CEO, Kissmetrics), Guy Kawasaki, the co-founder of Huddle, and the founders of AngelPad.

The Next Web (TNW) is one of the world’s largest online publications that delivers an international perspective on the latest news about Internet technology, business and culture, with an active, influential audience consisting of more than 5.1 million monthly visits and over 7 million monthly page views.



26 September 2011

Boutique corporate finance house, Epiphany Capital, has raised a pre-clinical round for Incanthera, a spin-out from the University of Bradford’s Institute of Cancer Therapeutics, which is led by Professor Laurence Patterson, from SPARK Ventures.

Incanthera has developed a novel drug delivery system for solid tumour chemotherapy, with impressive pre-clinical results to date, which has been featured widely in the press. (BBC News, FOX News, Financial Times).

Epiphany was involved in shaping the opportunity and building its management team prior to fundraising and spin-out.


January 2016

Epiphany Capital has raised a growth round for Instrumentel, world leading manufacturer of electronics systems for precision measurement in extreme environments, based in Leeds.

The £775k growth capital deal was led by private office, Alycidon Capital, who were joined by the University of Leeds, and Manchester Venture Partners (Epiphany’s side-car fund).

Instrumentel has a strong presence in the rail industry, the company has undertaken high value projects for major players including Angel Trains, East Coast Trains, First ScotRail and London Underground.

For more information on this deal, please contact Tim Dempsey.

06 Jan 2016

January 2016

PushDoctor.co.uk, Europe’s largest online GP marketplace has raised an $8.2million round of Series A financing, advised by Epiphany Capital.

The round was jointly led by Oxford Capital Partners and Draper Esprit, alongside Partech Ventures. The Company now sits with global disrupters including Lyst and TrustPilot, in the stables that have previously been the home of Skype, Baidu and Tesla.

PushDoctor.co.uk is changing the way everyone can access healthcare using its on-demand online GP surgery, making healthcare accessible for the tens of millions of people in the UK who find seeing a doctor difficult.

The Care Quality Commission-regulated and NHS-commissioned service allows patients to book and attend secure video GP appointments seven days per week, 365 days of the year, via a website and iOS app.

The Company had previously raised a $1.2 million seed round, also advised by Epiphany, now bringing its total funding to date to $9.4million.

PushDoctor.co.uk plans to use the investment to strengthen its brand position as category leader, carry out further product innovations, expand the business’ management structure, including making key marketing and product hires and to further its industry-connectivity; offering patients a simpler and more powerful set of routes into the healthcare eco-system.

Eren Ozagir, founder and CEO at PushDoctor.co.uk, comments: “PushDoctor.co.uk is the category leading digital primary care provider and will continue to work to provide UK patients with the ability to see a doctor whenever they want in a matter of minutes, at a price that is affordable and super-sustainable.

Ozagir continues: “We are all about usage, we want patients to get the advice they want from real doctors, in person and at a time that is convenient for them. This investment will allow us to continue to deliver important step-changes in digital health. We believe that having the ability to see a doctor on-demand speeds up the patient journey to recovery and that every patient should have the choice to reach for professional advice when they need to.”

As part of the deal, Oxford Capital Partners managing director, Tom Bradley and Draper Esprit partner, Vishal Gulati will both join the PushDoctor.co.uk board as non-executive directors.

Tom Bradley said: “We are excited to be working with the PushDoctor.co.uk team, who are truly creating a digital healthcare brand for the long term; a brand that people will turn to in important moments – for real help. It has the potential to change lives with each and every connection.

Bradley continues: “The service is uniquely positioned to provide UK patients with the next level of digitised medical services and a super fast connection to all parts of the healthcare eco-system – literally in minutes you can get a referral letter and activate your medical insurance, or receive a prescription for the medication you need. This is something that most patients will have never experienced before.”

Vishal Gulati commented: “With developments in digital technologies, access to high quality medical care which serves patients’ needs in the most appropriate manner should not be limited by the constraints of physical location. PushDoctor.co.uk is a highly valuable point of connection that assists patients to find their way through their individual care journeys – and it will continue especially as the industry itself digitizes.

“I am very pleased to be joining the PushDoctor.co.uk team and look forward to working with them to continue to provide a hugely valuable human connection for patients who want answers in real-time from a live medical professional, both efficiently and on their own terms.”

The business was established in early 2013, after Ozagir fell ill while overseas and noticed a gap in the market for primary care from UK-based doctors on the go, and became the first On-Demand Remote Care provider to launch in the UK App Store. PushDoctor.co.uk has since grown to become the fastest-growing clinician network in the country.

The platform enables patients to connect to qualified GMC registered private GPs in minutes in a HIPAA-approved video-surgery, and patients benefit from instant access to professional medical advice from a UK doctor who can prescribe, refer or provide a sick note.

The service charges £25 for a 10-minute appointment with a General Medical Council-regulated GP, while prescriptions are £4.50 and referral letters or fit for work notes are £12.50.

PushDoctor.co.uk was advised by Tim Dempsey of Epiphany Capital and Jonathan Gillow from Hill Dickinson LLP whilst Oxford Capital Partners and Draper Esprit were advised by Barry Maytum of Keystone Law LLP.

For more information on this deal, please contact Tim Dempsey.

Epiphany’s Managing Partner, Tim Dempsey today gave a talk to the Duke of York and some of the UK’s key business leaders as part of [email protected] On Tour, at the Sharp Project in Manchester.

Tim spoke about business models, addressable markets, positioning and competitive landscapes.

Manchester Evening News coverage of the event: here

SuperCarer - image 4

September 2015

Home-care marketplace, SuperCarers has closed a large seed round, assisted by Epiphany Capital. Investors include JamJar Investments (founders of Innocent Drinks), Stephen Critchlow (founder of Ascribe PLC), Sir Tom Hughes-Hallett (former Chief Executive of Marie Curie; Director, Kings Fund) and Manchester Venture Partners (Epiphany Capital’s sidecar fund).

Brothers Adam and Daniel Pike founded SuperCarers after watching their mother struggle to cope with managing their grandma’s care. Although she wanted to stay at home, the care was expensive, inconsistent and poor quality, leaving Adam & Daniel’s mother to see to her needs.

The platform is endorsed by care experts, including the former Care Minister from the Department of Health, Strategy Director of the Care Quality Commission (CQC).

For more information on this deal, please contact Tim Dempsey.

Epiphany Capital has raised a seed round for computer vision specialists, Digital Bridge.

Epiphany Capital has raised a pre-clinical round for Spanish ophthalmological drug development company, Bionure.


January 2015

Epiphany Capital has put together a seed round for PropertyMoose, one of the UK’s leading countrywide property crowdfunding platforms.

Property Moose was founded by Andrew Gardiner, a corporate lawyer who, during his career, put together the first and largest crowdfunding deals in the UK.

As part of the round, former Metro Bank senior executive, Darren Schindler, has joined the board as chairman.

For more information on the deal, please contact Tim Dempsey.

Tissue engineering company, Videregen, has successfully closed a £1.4m first round assisted by Epiphany Capital. The company is a spin-out from the Northwick Park Institute for Medical Research.

Videregen, led by the former team of Tissue Science Laboratories (now part of Covidien) together with Prof. Martin Birchall of University College London, holds a game changing new approach to regeneration which, having already demonstrated clinical efficacy, could eliminate the need for donor organs.

The technology, uses the patient’s own stem cells and a biocompatible, non-immunogenic scaffold to generate healthy tissue with which to repair the defective organ. This negates the need for donor organs, and with it, the requirement for immune-suppressant drugs, their associated costs and side-effects.

There are three people breathing independently today as a result of tracheal regeneration enabled by this technology, which has applications in bowel, liver and kidney.

The deal was put together by Epiphany’s Simon Bayly and Tim Dempsey and won ‘Deal of the Month’ for Insider Magazine.

For more information please contact Simon Bayly.

On-demand doctor surgery, Push DR has completed a funding round with some of the UK’s most successful entrepreneurs as investors, advised by Tim Dempsey at Epiphany Capital.

For more information on the deal, please contact Tim Dempsey.

Epiphany Capital has successfully advised Brainomix on their Series A round, with investors including Chimera Partners, Parkwalk and ISIS.

A University of Oxford start-up company, Brainomix is aiming to dramatically improve stroke treatment by developing software that gives all hospitals and clinics access to reliable diagnoses for their patients.

Co-founder Prof. Alastair Buchan, is the inventor of the ASPECTS system for stroke assessment, which has been demonstrated to significantly improve patient outcomes. However, its accuracy is often impaired by human subjectivity and its utility is severely limited by a lack of expert clinicians.

Brainomix e-ASPECTS software is the first system to provide automated and standardised analysis of CT brain scans for stroke damage, assessing patients’ suitability for life saving treatment. It has strong potential to become an indispensable tool in stroke care and generate substantial health economic benefits.

For more information on the deal, please contact Tim Dempsey or Simon Bayly.

1 2 3 4
What's New

Copyright 2016 Epiphany Capital